Sports performance research ↗ · Military & occupational performance ↗

OCCUPATIONAL MEDICINE / SOURCE RECORDS

Gazprom peptide research.

Occupational studies of Gazprom workers in the Russian Far North, including tissue-peptide programs and measures of adaptation to the work environment.

Findings from selected studies

  • Sick leave among 113 workers

    During an individually assigned, multi-preparation program, days unfit for work fell from 119 to 60 compared with the preceding year. There was no concurrent control group, and the difference in seasonal illness was inconclusive.

Browse study findings by subject ↓

Educational information only, not medical advice. Seek qualified healthcare help for medical conditions. This collection does not establish protection from industrial chemicals, cold or other workplace hazards.

The 113-worker Urengoy report

The original 2016 paper records 18 → 10 sick-leave certificates and 119 → 60 days unfit for work in 2014 versus 2015. Seasonal morbidity did not improve reliably. This was a historical comparison of a personalized program, with no concurrent control.

The paper names Endoluten, Vesugen, Crystagen, Pinealon and Cartalax; Cerluten also appears in the risk-based assignments. These are shared program results, not separate product effects. Its narrative 43.4% reduction does not match the table’s 119 → 60 days.

2016Uncontrolled human reportFull text available

Personified prevention of diseases under the conditions of the Far North

Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments · Journal publication

S. Trofimova, A. Trofimov, A. Koryakin, A. Chubukin, V. Ternovoy · Vrach. 2016;(6):64–66

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

Results and tables

Reported findings and study design

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Population or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Dose, route and schedule

One capsule of the assigned preparation daily for 20 days. Products were selected by risk assessment; all six products were not given to every participant.

Protocol source ↗ · Original PDF p.65

Results · Original publisher PDF pp.64–66; Table 2 visually checked
MeasureResultComparison, timing and statistics
Sick-leave certificates18 → 102014 → 2015; whole program
Days unfit for work119 → 602014 → 2015; whole program
Seasonal morbidityNo statistically reliable improvement reported
Narrative/table discrepancyNarrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Table 2 · Chronic-disease recurrence-related sick leave
Table 2 · Chronic-disease recurrence-related sick leave
Measure20142015
Sick-leave certificates1810
Days unfit for work11960

Historical comparison for the shared 113-worker program. Not preparation-specific results.

One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Source reviewed
Original publisher PDF methods and clinical table checked; table visually verified.
Study limitations
  • One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Reviewed 2026-11-01.

Read the source ↗

What can the other sources establish?

The congress citation, program narrative and dissertation are different documents. They should not be counted as three independent trials. The complete protocol and dissertation are needed to verify preparations, comparison groups and participant numbers for each outcome.

Which peptides were involved?

The dissertation excerpts name Thymalin, Epithalamin and Cortexin in sequential treatment for dyscirculatory encephalopathy. That does not establish what every program participant received. These tissue-derived preparations are distinct from synthetic Vilon, Epitalon, Pinealon and Vesugen.

Reported outcomes need their original tables

The reproduced narrative reports HDL +35%, VLDL -53% and LDL -30%; ultrasound improvement in thyroid, prostate and liver subgroups is reported as 61%, 41% and 35%. Follow-up imaging is described at approximately four, eight and twelve months. These findings require subgroup denominators, baseline data and control comparisons. Imaging changes do not independently demonstrate tissue regeneration.

Read the reproduced program narrative ↗

Core source records

2001Study design unresolvedBibliographic record

Program of Age-Related Pathology Prevention and Professional Longevity Extension among Gazprom Personnel

· Conference citation in author bibliography

R. I. Vyakhirev, N. N. Gouslisty, S. V. Okhotnikov, V. Kh. Khavinson · 17th World Congress of the International Association of Gerontology; Gerontology 47(Suppl. 1):453-454

The author bibliography lists a Vancouver congress abstract in Gerontology 47, Supplement 1, pages 453-454. This confirms a publication trail, not clinical efficacy.

Population / setting
Gazprom personnel; abstract-level participant details unavailable
Source reviewed
Author bibliography checked; abstract text not obtained.
Study limitations
  • Conference abstract and original protocol not recovered.
  • A bibliographic listing does not verify intervention identity, allocation or outcomes.

Reviewed 2026-10-02.

Read the source ↗
Year unconfirmedUncontrolled human reportRussian-language source

Программа продления активного профессионального долголетия работников ОАО «Газпром» — Program for extending active professional longevity of Gazprom employees

Individualized bioregulating interventions; exact formulations unresolved · Program report / commercial reproduction

· Program narrative reproduced by Vitual; publication date unconfirmed

The reproduced report describes 11,192 employees reached during March-November 2000. It claims 2.3-fold lower overall morbidity and 2.7-fold lower seasonal infectious morbidity. These are report-level claims, not independently established treatment effects.

Population / setting
Gazprom occupational program; analyzed subgroups and denominators unresolved
Source reviewed
Accessible Russian narrative checked. Image-based tables and original program documentation require independent appraisal.
Study limitations
  • Commercial reproduction; original signed report and underlying data not obtained.
  • Outcome-specific denominators, allocation, confounding, adverse events and exact formulations need verification.
  • Program reach is not the number contributing to every outcome; no modern synthetic peptide inherits these results.

Reviewed 2026-10-02.

Read the source ↗
2003Study design unresolvedBibliographic record

Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions

Thymalin, Epithalamin and Cortexin tissue-derived preparations · Dissertation record and indexed excerpts

Vladimir Alekseevich Cherkashin · Candidate of Medical Sciences dissertation, St. Petersburg, 2003; 203 pages

The dissertation trail links examinations of Gazprom employees and family members to the program approved in February 2000. Indexed recommendations name sequential Thymalin, Epithalamin and Cortexin for a disease-specific setting; they do not establish a universal occupational regimen.

Population / setting
Far North clinical research associated with Gazprom employees and families; exact cohort allocation unresolved
Source reviewed
Available sources include bibliographic metadata and dissertation excerpts. The complete thesis was unavailable for review.
Study limitations
  • Full 203-page dissertation has not been obtained.
  • Search-indexed excerpts are not a substitute for original methods and tables.
  • Named sequential therapy for dyscirculatory encephalopathy does not identify treatment for every Gazprom employee.
  • Overlap with the broader program and other clinical cohorts remains unresolved.

Reviewed 2026-10-02.

Read the source ↗

Dissertation and bibliography priorities

Cherkashin: complete dissertation · 2002 thymus/pineal monograph · 2001 aging monograph lead

Priority sections are participant selection, treatment identity, allocation, adverse events, original outcome tables and the bibliography. A commercial acquisition listing is not a verified PDF download.

Research / acquisition lead

Northern occupational physiology

Krivoshonov and Okhotnikov (2000), Production Migration and Human Health in the North. Full publication details remain uncertain.

Research / acquisition lead

Cerebral circulation

Krivoshapkin (1993) cerebral-ischemia work and the Epithalamin/Cortexin traumatic-brain-injury dissertation are related acquisition leads, not Gazprom trial results.

Research / acquisition lead

Experimental toxicity

The 2004 Lebnikova/Zhamsaranova 2,4-D herbicide paper requires primary-paper retrieval. It cannot establish benzene or hydrogen-sulfide protection.

Research / acquisition lead

Cold-stress research

Arokina and colleagues (2022) describe a vascular polypeptide complex in rats. The formulation and its relationship to Vesugen remain unclear.

Research / acquisition lead

Modern Arctic occupational health

The Gazprom Dobycha Yamburg cardiovascular-risk dissertation concerns occupational risk; it is not automatically a peptide intervention study.

Research / acquisition lead

Cohort overlap

Compare the dissertation, conference abstract, program narrative and long-term gerontology publications. Shared authors or similar treatments neither prove independence nor prove shared participants.

Research / acquisition lead

Reporting discrepancies

Secondary accounts describe different sample totals, controls, durations and preparations. Original protocols and independent corroboration are needed before reconciling these versions or publishing mortality claims.

Historical combinations matrix · Citable research library

Study findings by subject

2 source records

Observational study

Программа продления активного профессионального долголетия работников ОАО «Газпром» — Program for extending active professional longevity of Gazprom employees

The reproduced report describes 11,192 employees reached during March-November 2000. It claims 2.3-fold lower overall morbidity and 2.7-fold lower seasonal infectious morbidity. These are report-level claims, not independently established treatment effects.

Methods and source ↗